Patents by Inventor Giangiacomo Torri
Giangiacomo Torri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11370848Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.Type: GrantFiled: February 21, 2020Date of Patent: June 28, 2022Assignee: Novahealth Biosystems, LLCInventors: Giangiacomo Torri, Annamaria Naggi
-
Patent number: 11332548Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.Type: GrantFiled: February 4, 2020Date of Patent: May 17, 2022Assignee: Novahealth Biosystems, LLCInventors: Giangiacomo Torri, Annamaria Naggi
-
Patent number: 11248063Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.Type: GrantFiled: March 18, 2020Date of Patent: February 15, 2022Assignee: Novahealth Biosystems, LLCInventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20210332162Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.Type: ApplicationFiled: March 18, 2020Publication date: October 28, 2021Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20210054108Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.Type: ApplicationFiled: March 18, 2020Publication date: February 25, 2021Inventors: Giangiacomo Torri, Annamaria Naggi
-
Patent number: 10875936Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glycosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glycosaminoglycan derivatives are obtained from natural or synthetic glycosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glycosaminoglycan by oxidation of said glycosaminoglycan.Type: GrantFiled: October 23, 2014Date of Patent: December 29, 2020Assignee: Novahealth Biosystems, LLCInventors: Giangiacomo Torri, Annamaria Naggi
-
Patent number: 10822430Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.Type: GrantFiled: October 22, 2014Date of Patent: November 3, 2020Assignee: Novahealth Biosystems, LLCInventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20200216577Abstract: A glycosaminoglycan derivative which is obtainable by a process that includes the steps of N-desulfation of from 25% to 100% of the N-sulfated residues of a glycosaminoglycan, and oxidation, by periodate at a pH of from 5.5 to 10.0, of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues, and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan, under conditions effective to convert adjacent diols and adjacent OH/NH2 to aldehydes. The process further includes reduction, by sodium borohydride, of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols, where the glycosaminoglycan is heparin, low molecular weight heparin, heparan sulfate or fractions thereof.Type: ApplicationFiled: March 18, 2020Publication date: July 9, 2020Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20200190224Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.Type: ApplicationFiled: February 21, 2020Publication date: June 18, 2020Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20200172636Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.Type: ApplicationFiled: February 4, 2020Publication date: June 4, 2020Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20170233501Abstract: The invention relates to glucosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glucosaminoglycan residues, and to the process for preparing the same. The glucosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glucosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glucosaminoglycan derivatives and further to their use as active ingredients of medicaments.Type: ApplicationFiled: October 22, 2014Publication date: August 17, 2017Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20160297896Abstract: The invention relates to glucosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glucosaminoglycan residues, and to the process for preparing the same. The glucosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glucosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glucosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glucosaminoglycan derivatives and further to their use as active ingredients of medicaments.Type: ApplicationFiled: October 22, 2014Publication date: October 13, 2016Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20160237178Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glucosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glucosaminoglycan derivatives are obtained from natural or synthetic glucosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glucosaminoglycan by oxidation of said glucosaminoglycan.Type: ApplicationFiled: October 23, 2014Publication date: August 18, 2016Applicant: CENTRO ALTA TECNOLOGIA ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE "G.RONZONI" S.R.Inventors: Giangiacomo Torri, Annamaria Naggi
-
Publication number: 20150100249Abstract: A method of analysis of a heterogeneous product, for example heparin or heparin derivatives, to define whether said heterogeneous product is consistent with a library of verified heterogeneous samples (Library 1) by analysing the variation, natural or alien. The acceptable variation of the heterogeneous product is determined by comparing Library 1 with a second set of verified spectra (Library 2), by use of comparative two-dimensional correlation spectroscopic filtering (comparative 2D-COS-f). The method comprises obtaining a one-dimensional complex spectrum, for example 1H-NMR spectra, of a heterogeneous product and testing if it has features that are greater than features found testing a spectrum from Library 2 against Library 1. In a second embodiment comparative 2D-COS-f with iterative random sampling (2D-COS-firs) is applied, which provides a more accurate and stable extraction of aliens/unnatural features.Type: ApplicationFiled: May 10, 2013Publication date: April 9, 2015Applicants: Istituto Di Ricerche Chimiche E Biochimiche "G. Ronzoni", Anglo-Italian Chemometrics LTD.Inventors: Giangiacomo Torri, Marco Guerrini, Timothy Robert Rudd
-
Patent number: 8853387Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.Type: GrantFiled: July 9, 2009Date of Patent: October 7, 2014Assignee: Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
-
Publication number: 20120232263Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.Type: ApplicationFiled: July 9, 2009Publication date: September 13, 2012Applicant: Istituto Scientifico Di Chimica E Biochimica "G" RInventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
-
Patent number: 8222231Abstract: Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.Type: GrantFiled: August 5, 2010Date of Patent: July 17, 2012Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SpAInventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
-
Patent number: 8067555Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.Type: GrantFiled: August 8, 2007Date of Patent: November 29, 2011Assignee: Sigma-Tau Research Switzerland S.A.Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
-
Patent number: 8018231Abstract: The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.Type: GrantFiled: May 5, 2010Date of Patent: September 13, 2011Assignees: Massachussetts Institute of Technology, Istituto di Ricerche Chimiche e Biochimiche G RonzoniInventors: Ram Sasisekharan, Ganesh Venkataraman, Rahul Raman, Benito Casu, Giangiacomo Torri, Marco Guerrini
-
Patent number: 7939512Abstract: The present invention is directed to a multistep process for the physical depolymerization of heparin wherein heparin is subjected to at least two ?-ray irradiations and wherein between two irradiation steps the depolymerised heparin is subjected to a separation step and only a fraction of the depolymerised heparin obtained from the first irradiation is subjected to the second irradiation step. It is also directed to heparin-derived oligosaccharide fractions obtainable by the process of the invention.Type: GrantFiled: April 13, 2006Date of Patent: May 10, 2011Assignee: Laboratori Derivati Organici SpAInventors: Luigi De Ambrosi, Sergio Gonella, Donata Bensi, Giangiacomo Torri, Antonella Bisio, Elena Vismara